Major Shareholding Notification • Oct 24, 2014
Major Shareholding Notification
Open in ViewerOpens in native device viewer
DISCLOSURE OF SHAREHOLDING IN MEDISTIM ASA
This joint disclosure is made by HealthInvest
Partners AB ("HealthInvest") for and on behalf of
itself as well as for and on behalf of HealthInvest
Value Fund and HealthInvest MicroCap Fund, in
accordance with Section 4-3 of the Norwegian
Securities Trading Act.
HealthInvest is an independent Swedish fund
management company under the supervision of the
Swedish Financial Supervisory Authority
(Finansinspektionen) since 2006. HealthInvest offers
actively managed healthcare funds aimed at
institutional and private clients. HealthInvest´s
investment approach includes a strong emphasis on low
valuations and in depth due diligence to find
potential catalysts to boost shareholder value.
On October 24, 2014 (with settle date October 28,
2014), HealthInvest acquired 50,000 shares in
MEDISTIM ASA ("MEDISTIM") for and on behalf of the
HealthInvest MicroCap Fund. As a result of the
transaction, HealthInvest MicroCap Fund and
HealthInvest Value Fund crossed the 5% threshold of
Section 4-3 of the Norwegian Securities Trading Act
calculated on an aggregate basis.
After the transaction mentioned above, HealthInvest
MicroCap Fund and HealthInvest Value Funds
shareholding in MEDISTIM amounts to 284,374 shares
and 665,196 shares respectively. This equals 1.57%
and 3.67% of the issued shares and votes in MEDISTIM.
After the transaction, the aggregate shareholding in
MEDISTIM over which HealthInvest is authorized to
exercise voting rights on a discretionary basis
amounts to 949,570 shares, equaling 5.25% of the
issued shares and votes in MEDISTIM.
The above calculations are based on a total number of
outstanding shares in MEDISTIM of 18,101,000 shares.
No rights to shares in MEDISTIM are held by
HealthInvest MicroCap Fund, HealthInvest Value Fund
or any other fund managed by HealthInvest.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.